Helena Earl

University of Cambridge — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

60h-index16.8kcitations355works15.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(109), Cancer Treatment and Pharmacology(64), HER2/EGFR in Cancer Research(51), Cancer Genomics and Diagnostics(42), Ovarian cancer diagnosis and treatment(38)

Publications350 total

315P SYNERGIA breast cancer: Automated assessment of tumour-infiltrating lymphocytes
Annals of Oncology·2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data
BMJ Oncology·2025· 2 citedOpen Access
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Nature Communications·2025· 8 citedOpen Access
190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study
ESMO Open·2025· 1 citedOpen Access
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
npj Breast Cancer·2025· 4 citedOpen Access
P215: NOSTRA-Feasibility: Predicting pathological complete response using multiple ultrasound-guided tumour bed core biopsies after neoadjuvant systemic therapy in HER-2 positive ER negative breast cancer
The Breast·2025Open Access
Non-inferiority trials: tyranny or good governance? – Authors' reply
The Lancet Oncology·2025
The tyranny of non-inferiority trials
The Lancet Oncology·2024· 25 cited
Primary culture of high grade serous ovarian cancer cells, selection and derivation of three cell lines
2024· 2 citedOpen Access
The Lancet Breast Cancer Commission
The Lancet·2024· 135 citedOpen Access
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Nature·2024· 38 citedOpen Access
Abstract CT012: PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
Cancer Research·2024· 1 cited
Safe de-escalation of chemotherapy in HER2-positive early breast cancer
The Lancet·2024· 1 cited
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Research Explorer (The University of Manchester)·2024Open Access
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
The Lancet Oncology·2023· 11 citedOpen Access
356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Annals of Oncology·2023· 1 citedOpen Access
Supplementary Tables 1 - 5, Figures 1 - 2 from Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
2023Open Access
Data from Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
2023Open Access
Data from Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
2023Open Access
Supplementary Tables 1 - 5, Figures 1 - 2 from Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Carlos Caldas(18), Janet Dunn(16), Louise Hiller(15), Elena Provenzano(14), Jean Abraham(14), David Cameron(14), Paul D.P. Pharoah(10), Daniel Rea(10), Christopher Poole(10), John M.S. Bartlett(9), S. Bowden(7), Karen McAdam(7), Sarah E. Pinder(6), James D. Brenton(6), Luke Hughes‐Davies(6), Stephen‐John Sammut(5), Sarah‐Jane Dawson(5), Ian O. Ellis(5), Andrew Wardley(5), Jeremy Thomas(5)